Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M
Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M
Karyopharm Therapeutics重申2024年的收入指導爲1.4億至1.6億美元,而市場共識爲1.4652億美元,其中包括1億至1.2億美元的美國XPOVIO淨產品收入指導
Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M
Karyopharm Therapeutics重申2024年的收入指導爲1.4億至1.6億美元,而市場共識爲1.4652億美元,其中包括1億至1.2億美元的美國XPOVIO淨產品收入指導